Stock Analysis
Elanco Animal Health Incorporated Common StockELAN
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy23 analystsPrice is 53% of the way from the year's low to its high.
Cash covers 14% of debt · FY 2025.
PMP Verdict
Weak fundamentals
Risks
- Growth0
- Profitability10
Weak fundamentals — valuation is the only support.
What's happening with ELAN
Profile
growth, profitability, moat, valuation and financial health lag behind.
How is each axis scored?
- Valuation42/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (3.3%)12/25
- P/S (2.3x)20/25
- EV/EBIT (44.0x)0/25
- Growth0/100 · Weak
- Revenue CAGR (-0.3%)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability10/100 · Weak
- ROIC (2.7%)5/25
- ROE (-3.0%)0/25
- Net margin (-4.0%)0/25
- Operating margin (6.8%)5/25
- Financial Health43/100 · Weak
- Altman Z (1.36)3/25
- Current ratio (2.17)25/25
- Interest coverage (1.3x)3/25
- Net cash / debt (D/A 26%)12/25
- Quality52/100 · Moderate
- Piotroski F (6/9)15/25
- Beneish M (-2.68)25/25
- FCF conversion (-190%)0/25
- Margin stability (σ 9.1%)12/25
- Moat38/100 · Weak
- ROIC >12% years (0/8 yrs)0/25
- Median gross margin (54.9%)20/25
- FCF-positive years (7/8 yrs)18/25
- Worst-year net margin (worst -27.9%)0/25
Risk Flags
- ⚠Altman Z 1.4 — distress-zone balance sheet
- ⚠5 loss-making years in recent history
- ⚠Interest coverage 1.3× — thin debt cushion
- ⚠Revenue shrinking 0.3%/yr
About Elanco Animal Health Incorporated Common Stock
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. Show more
It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
Headquarters: INDIANAPOLIS, IN · Employees: 9,900 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
42D+P/E (TTM)—
Price / TTM EPS (own statements)
P/FCF28.2xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield3.3%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -1.1%–12.2% · 45th pct
P/S (TTM)2.29xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 0.9x–3.5x · 71st pct
EV/EBIT44.0xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 14.8x–71.5x · 80th pct
EV/Sales3.0xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E20.7xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio1.76xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
10EROIC2.7%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-3.0%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-1.5%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-4.0%D
Grade D: LowNet Income / Revenue
Operating Margin6.8%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin55.4%A
Grade A: PremiumGross Profit / Revenue
FCF Margin7.5%D
Grade D: LowFCF / Revenue
True FCF Margin6.1%C
Grade C: AverageTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR-0.3%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+2.6%C
Grade C: DilutiveShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.5%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
43D+Altman Z-Score1.36D
Grade D: DistressBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.17xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio0.91xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage1.3xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment9.2yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT10.2xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity0.61xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.14xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
52CPiotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.68A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion-190.5%D
Grade D: PoorFCF / Net Income
Margin Stability9.1%C
Grade C: AverageEBIT margin std deviation. Lower = stable
Capex / Revenue4.7%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.37xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Modi Rajeev A. Filed | Modi Rajeev A. | Grant / award | +67 | |
VanHimbergen Robert M Filed | VanHimbergen Robert M | Grant / award | +9 | |
Simmons Jeffrey N Filed | Simmons Jeffrey N | Grant / award | +128 | |
Anand Kapila K Filed | Anand Kapila K | Grant / award | +642 | |
Modi Rajeev A. Filed | Modi Rajeev A. | Grant / award | +66 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
VanHimbergen Robert M Filed | VanHimbergen Robert M | Grant / award | +9 | |
Simmons Jeffrey N Filed | Simmons Jeffrey N | Grant / award | +126 | |
Modi Rajeev A. Filed | Modi Rajeev A. | Grant / award | +60 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
38DROIC >12% Years0/8 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)54.9%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years7/8 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-27.9%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$1.06
Cash & short-term investments per share (Finnhub)
Book Value / Share$13.19
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$4.02B
Total debt obligations (short + long term)
Cash & Equiv.$545.00M
Cash and short-term investments
Net Debt$3.47B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$6.55B
Shareholders' equity (book value)
Asset / Liability1.96xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$11.50B
Current Market Capitalization
Beta1.75C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Elanco Animal Health Incorporated Common Stock (ELAN)
Piotroski F-Score of 6/9 indicates mixed fundamentals for Elanco Animal Health Incorporated Common Stock. Altman Z-Score of 1.36 is below the 1.81 distress threshold — an elevated financial-risk flag. Beneish M-Score of -2.68 suggests a low likelihood of earnings manipulation. Revenue has been contracting (CAGR ≈ -0%), which weighs on the growth outlook.
- Takes ~9.2 years to repay net debt from free cash flow.
- Interest coverage of 1.3× leaves little room for earnings shocks.
- Elanco Animal Health Incorporated Common Stock posted a net loss in 5 of 8 available completed fiscal years (2018–2025).
See how ELAN ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all ELAN moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 23.49 | +4.17% | 3.14 |
| Oct 5 | Regular | 22.69 | +2.46% | 2.12 |
| Sep 22 | Regular | 23.07 | +2.85% | 2.10 |
Frequently Asked Questions about ELAN
What is the current Elanco Animal Health Incorporated Common Stock (ELAN) stock price?
ELAN is trading at $23.55 at the last market close, up 0.04% on the session. PreMarketPrice tracks ELAN pre-market, intraday and after-hours prices.
Is ELAN stock a buy right now?
PreMarketPrice's quantitative model rates Elanco Animal Health Incorporated Common Stock's financial health at 43/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is ELAN stock overvalued?
Elanco Animal Health Incorporated Common Stock trades at a trailing P/E of n/a and our valuation score rates it 42/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Elanco Animal Health Incorporated Common Stock report earnings?
No confirmed earnings date is currently scheduled for ELAN. The Earnings section lists recent reports and updates as dates are announced.
What sector does Elanco Animal Health Incorporated Common Stock operate in?
Elanco Animal Health Incorporated Common Stock operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Elanco Animal Health Incorporated Common Stock do?
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals.
About Elanco Animal Health Incorporated Common Stock (ELAN) Stock
Elanco Animal Health Incorporated Common Stock (ELAN) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, Elanco Animal Health Incorporated Common Stock is trading at $23.55, up 0.04% on the day with a market capitalization of $11.5 billion. The financial health score for ELAN is 43/100, which indicates weak financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for ELAN stock.
ELAN Stock Analysis & Key Metrics
On PreMarketPrice, you can track Elanco Animal Health Incorporated Common Stock (ELAN) across multiple dimensions:
- Pre-market price & movement: Real-time ELAN stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for ELAN with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Elanco Animal Health Incorporated Common Stock across multiple reporting periods.
- Financial health score: A composite score of 43/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for ELAN.
- Sector peers: Compare ELAN against 6 other healthcare stocks on key financial metrics.
Is ELAN a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Elanco Animal Health Incorporated Common Stock (ELAN) as an investment. The financial health score of 43/100 suggests weak financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Elanco Animal Health Incorporated Common Stock (ELAN) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.